United States Pulmonary Arterial Hypertension Drugs Market Report 2016

November 2016 | 98 pages | ID: U024CCA49A1EN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Pulmonary Arterial Hypertension Drugs

Revenue, means the sales value of Pulmonary Arterial Hypertension Drugs

This report studies sales (consumption) of Pulmonary Arterial Hypertension Drugs in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• Actelion Pharmaceuticals Ltd.
• United Therapeutics Corporation
• Gilead sciences
• Bayer AG
• SteadyMed Ltd.
• GlaxoSmithKline plc
• Pfizer Inc.
• Reata Pharmaceuticals Inc.
• Arena Pharmaceuticals Inc.
• Merck & Co. Inc

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Type I
• Type II
• Type III

Split by applications, this report focuses on sales, market share and growth rate of Pulmonary Arterial Hypertension Drugs in each application, can be divided into

• Application 1
• Application 2
• Application 3

Contents

United States Pulmonary Arterial Hypertension Drugs Market Report 2016

1 PULMONARY ARTERIAL HYPERTENSION DRUGS OVERVIEW

1.1 Product Overview and Scope of Pulmonary Arterial Hypertension Drugs
1.2 Classification of Pulmonary Arterial Hypertension Drugs
  1.2.1 Type I
  1.2.2 Type II
  1.2.3 Type III
1.3 Application of Pulmonary Arterial Hypertension Drugs
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Pulmonary Arterial Hypertension Drugs (2011-2021)
  1.4.1 United States Pulmonary Arterial Hypertension Drugs Sales and Growth Rate (2011-2021)
  1.4.2 United States Pulmonary Arterial Hypertension Drugs Revenue and Growth Rate (2011-2021)

2 UNITED STATES PULMONARY ARTERIAL HYPERTENSION DRUGS COMPETITION BY MANUFACTURERS

2.1 United States Pulmonary Arterial Hypertension Drugs Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Pulmonary Arterial Hypertension Drugs Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Pulmonary Arterial Hypertension Drugs Average Price by Manufactures (2015 and 2016)
2.4 Pulmonary Arterial Hypertension Drugs Market Competitive Situation and Trends
  2.4.1 Pulmonary Arterial Hypertension Drugs Market Concentration Rate
  2.4.2 Pulmonary Arterial Hypertension Drugs Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES PULMONARY ARTERIAL HYPERTENSION DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States Pulmonary Arterial Hypertension Drugs Sales and Market Share by Type (2011-2016)
3.2 United States Pulmonary Arterial Hypertension Drugs Revenue and Market Share by Type (2011-2016)
3.3 United States Pulmonary Arterial Hypertension Drugs Price by Type (2011-2016)
3.4 United States Pulmonary Arterial Hypertension Drugs Sales Growth Rate by Type (2011-2016)

4 UNITED STATES PULMONARY ARTERIAL HYPERTENSION DRUGS SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States Pulmonary Arterial Hypertension Drugs Sales and Market Share by Application (2011-2016)
4.2 United States Pulmonary Arterial Hypertension Drugs Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 UNITED STATES PULMONARY ARTERIAL HYPERTENSION DRUGS MANUFACTURERS PROFILES/ANALYSIS

5.1 Actelion Pharmaceuticals Ltd.
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 Actelion Pharmaceuticals Ltd. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 United Therapeutics Corporation
  5.2.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 United Therapeutics Corporation Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 Gilead sciences
  5.3.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 Gilead sciences Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 Bayer AG
  5.4.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 Bayer AG Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 SteadyMed Ltd.
  5.5.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 SteadyMed Ltd. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 GlaxoSmithKline plc
  5.6.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 GlaxoSmithKline plc Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 Pfizer Inc.
  5.7.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 Pfizer Inc. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Reata Pharmaceuticals Inc.
  5.8.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Reata Pharmaceuticals Inc. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 Arena Pharmaceuticals Inc.
  5.9.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 Arena Pharmaceuticals Inc. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 Merck & Co. Inc
  5.10.2 Pulmonary Arterial Hypertension Drugs Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 Merck & Co. Inc Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview

6 PULMONARY ARTERIAL HYPERTENSION DRUGS MANUFACTURING COST ANALYSIS

6.1 Pulmonary Arterial Hypertension Drugs Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension Drugs

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 Pulmonary Arterial Hypertension Drugs Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Pulmonary Arterial Hypertension Drugs Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 UNITED STATES PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET FORECAST (2016-2021)

10.1 United States Pulmonary Arterial Hypertension Drugs Sales, Revenue Forecast (2016-2021)
10.2 United States Pulmonary Arterial Hypertension Drugs Sales Forecast by Type (2016-2021)
10.3 United States Pulmonary Arterial Hypertension Drugs Sales Forecast by Application (2016-2021)
10.4 Pulmonary Arterial Hypertension Drugs Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Disclosure Section
Research Methodology
Data Source
Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Pulmonary Arterial Hypertension Drugs
Table Classification of Pulmonary Arterial Hypertension Drugs
Figure United States Sales Market Share of Pulmonary Arterial Hypertension Drugs by Type in 2015
Table Application of Pulmonary Arterial Hypertension Drugs
Figure United States Sales Market Share of Pulmonary Arterial Hypertension Drugs by Application in 2015
Figure United States Pulmonary Arterial Hypertension Drugs Sales and Growth Rate (2011-2021)
Figure United States Pulmonary Arterial Hypertension Drugs Revenue and Growth Rate (2011-2021)
Table United States Pulmonary Arterial Hypertension Drugs Sales of Key Manufacturers (2015 and 2016)
Table United States Pulmonary Arterial Hypertension Drugs Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Pulmonary Arterial Hypertension Drugs Sales Share by Manufacturers
Figure 2016 Pulmonary Arterial Hypertension Drugs Sales Share by Manufacturers
Table United States Pulmonary Arterial Hypertension Drugs Revenue by Manufacturers (2015 and 2016)
Table United States Pulmonary Arterial Hypertension Drugs Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Pulmonary Arterial Hypertension Drugs Revenue Share by Manufacturers
Table 2016 United States Pulmonary Arterial Hypertension Drugs Revenue Share by Manufacturers
Table United States Market Pulmonary Arterial Hypertension Drugs Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Pulmonary Arterial Hypertension Drugs Average Price of Key Manufacturers in 2015
Figure Pulmonary Arterial Hypertension Drugs Market Share of Top 3 Manufacturers
Figure Pulmonary Arterial Hypertension Drugs Market Share of Top 5 Manufacturers
Table United States Pulmonary Arterial Hypertension Drugs Sales by Type (2011-2016)
Table United States Pulmonary Arterial Hypertension Drugs Sales Share by Type (2011-2016)
Figure United States Pulmonary Arterial Hypertension Drugs Sales Market Share by Type in 2015
Table United States Pulmonary Arterial Hypertension Drugs Revenue and Market Share by Type (2011-2016)
Table United States Pulmonary Arterial Hypertension Drugs Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Pulmonary Arterial Hypertension Drugs by Type (2011-2016)
Table United States Pulmonary Arterial Hypertension Drugs Price by Type (2011-2016)
Figure United States Pulmonary Arterial Hypertension Drugs Sales Growth Rate by Type (2011-2016)
Table United States Pulmonary Arterial Hypertension Drugs Sales by Application (2011-2016)
Table United States Pulmonary Arterial Hypertension Drugs Sales Market Share by Application (2011-2016)
Figure United States Pulmonary Arterial Hypertension Drugs Sales Market Share by Application in 2015
Table United States Pulmonary Arterial Hypertension Drugs Sales Growth Rate by Application (2011-2016)
Figure United States Pulmonary Arterial Hypertension Drugs Sales Growth Rate by Application (2011-2016)
Table Actelion Pharmaceuticals Ltd. Basic Information List
Table Actelion Pharmaceuticals Ltd. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Actelion Pharmaceuticals Ltd. Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table United Therapeutics Corporation Basic Information List
Table United Therapeutics Corporation Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table United Therapeutics Corporation Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table Gilead sciences Basic Information List
Table Gilead sciences Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table Gilead sciences Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table Bayer AG Basic Information List
Table Bayer AG Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table Bayer AG Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table SteadyMed Ltd. Basic Information List
Table SteadyMed Ltd. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table SteadyMed Ltd. Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table GlaxoSmithKline plc Basic Information List
Table GlaxoSmithKline plc Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table GlaxoSmithKline plc Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table Pfizer Inc. Basic Information List
Table Pfizer Inc. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table Pfizer Inc. Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table Reata Pharmaceuticals Inc. Basic Information List
Table Reata Pharmaceuticals Inc. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table Reata Pharmaceuticals Inc. Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table Arena Pharmaceuticals Inc. Basic Information List
Table Arena Pharmaceuticals Inc. Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table Arena Pharmaceuticals Inc. Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table Merck & Co. Inc Basic Information List
Table Merck & Co. Inc Pulmonary Arterial Hypertension Drugs Sales, Revenue, Price and Gross Margin (2011-2016)
Table Merck & Co. Inc Pulmonary Arterial Hypertension Drugs Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pulmonary Arterial Hypertension Drugs
Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension Drugs
Figure Pulmonary Arterial Hypertension Drugs Industrial Chain Analysis
Table Raw Materials Sources of Pulmonary Arterial Hypertension Drugs Major Manufacturers in 2015
Table Major Buyers of Pulmonary Arterial Hypertension Drugs
Table Distributors/Traders List
Figure United States Pulmonary Arterial Hypertension Drugs Production and Growth Rate Forecast (2016-2021)
Figure United States Pulmonary Arterial Hypertension Drugs Revenue and Growth Rate Forecast (2016-2021)
Table United States Pulmonary Arterial Hypertension Drugs Production Forecast by Type (2016-2021)
Table United States Pulmonary Arterial Hypertension Drugs Consumption Forecast by Application (2016-2021)